Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04172714 · ClinicalTrials.gov registry record · NA
Low-dose Y90 Treatment Planning for HCC
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT04172714 is a NA study that has completed, run by Emory University. The registered enrollment target is 30 participants.
The verdict
NCT04172714, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The study proposes low-dose Y90 microspheres for therapy planning of HCC, as an alternative to Technetium (99mTc) albumin aggregated (MAA), to be a bioidentical therapeutic Y90 surrogate marker to better predict and thus achieve optimal therapeutic dosing.
Interventions
- DEVICE SIR-Spheres microspheres
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-12-16 |
| Est. Completion | 2021-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04172714
The ClinicalTrials.gov registry entry for NCT04172714 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SIR-Spheres microspheres is the first listed.
NCT04172714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04172714 about?
NCT04172714 is a clinical study titled "Low-dose Y90 Treatment Planning for HCC". The study proposes low-dose Y90 microspheres for therapy planning of HCC, as an alternative to Technetium (99mTc) albumin aggregated (MAA), to be a bioidentical therapeutic Y90 surrogate marker to better predict and thus achieve optimal therapeutic dosing.
What is the current status of trial NCT04172714?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2019-12-16. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT04172714?
The interventions under investigation include: SIR-Spheres microspheres (DEVICE).
Who is sponsoring clinical trial NCT04172714?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.